Log in

NASDAQ:DNLIDenali Therapeutics Stock Price, Forecast & News

$31.61
-0.05 (-0.16 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$31.21
Now: $31.61
$34.88
50-Day Range
$23.13
MA: $24.98
$31.66
52-Week Range
$12.39
Now: $31.61
$35.70
Volume1.36 million shs
Average Volume774,140 shs
Market Capitalization$3.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California.
Read More
Denali Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.98 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.68 million
Book Value$4.11 per share

Profitability

Net Income$-197,610,000.00
Net Margins-778.32%

Miscellaneous

Employees179
Market Cap$3.34 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$31.61
-0.05 (-0.16 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

How has Denali Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DNLI stock has increased by 87.3% and is now trading at $31.61.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Denali Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Denali Therapeutics
.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Denali Therapeutics
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc (NASDAQ:DNLI) issued its quarterly earnings results on Friday, August, 7th. The company reported ($0.56) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.61) by $0.05. Denali Therapeutics had a negative net margin of 778.32% and a negative return on equity of 46.97%.
View Denali Therapeutics' earnings history
.

What price target have analysts set for DNLI?

10 equities research analysts have issued twelve-month target prices for Denali Therapeutics' stock. Their forecasts range from $20.00 to $37.00. On average, they expect Denali Therapeutics' stock price to reach $29.78 in the next year. This suggests that the stock has a possible downside of 5.8%.
View analysts' price targets for Denali Therapeutics
.

Has Denali Therapeutics been receiving favorable news coverage?

News headlines about DNLI stock have been trending negative on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Denali Therapeutics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Denali Therapeutics
.

Are investors shorting Denali Therapeutics?

Denali Therapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 9,850,000 shares, a decrease of 11.3% from the July 15th total of 11,110,000 shares. Based on an average daily trading volume, of 520,100 shares, the days-to-cover ratio is presently 18.9 days. Currently, 13.6% of the shares of the company are short sold.
View Denali Therapeutics' Short Interest
.

Who are some of Denali Therapeutics' key competitors?

What other stocks do shareholders of Denali Therapeutics own?

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 43)
  • Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 46)
  • Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 59)
  • Mr. Steve E. Krognes, CFO & Treasurer (Age 50)
  • Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 46)

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.42%), Principal Financial Group Inc. (0.19%), Swiss National Bank (0.17%), Broderick Brian C (0.08%), Wellington Shields & Co. LLC (0.07%) and New York State Common Retirement Fund (0.05%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts and Steve E Krognes.
View institutional ownership trends for Denali Therapeutics
.

Which major investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Russell Investments Group Ltd., UBS Group AG, Virtus ETF Advisers LLC, Principal Financial Group Inc., SG Americas Securities LLC, and Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, and Steve E Krognes.
View insider buying and selling activity for Denali Therapeutics
.

Which major investors are buying Denali Therapeutics stock?

DNLI stock was acquired by a variety of institutional investors in the last quarter, including Broderick Brian C, Wellington Shields & Co. LLC, Wellington Shields Capital Management LLC, Swiss National Bank, Rafferty Asset Management LLC, New York State Common Retirement Fund, Quantitative Systematic Strategies LLC, and ProShare Advisors LLC.
View insider buying and selling activity for Denali Therapeutics
.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $31.61.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $3.34 billion and generates $26.68 million in revenue each year. The company earns $-197,610,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.